Odonate Therapeutics, Inc.
DelistedCIK 1717452fmd_1GBDR3GGQCMHZCEXFC5AFZEM3AManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2021, 19 periods
Latest annual · FY2020
Millions- Operating income
- (127)
- Net income
- (126)
- Free cash flow
- (114)
Latest quarter · Q3 FY2021
Millions- Operating income
- (14)
- Net income
- (14)
- Free cash flow
- (15)
Odonate Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2020 | FY2019 | Change | Source |
|---|---|---|---|---|
| Operating income | -$127.4 million | -$114.9 million | 10-K 2021-02-23 · proof | |
| Net income | -$126.4 million | -$111.8 million | 10-K 2021-02-23 · proof | |
| Cash from operating activities | -$113.1 million | -$96.6 million | 10-K 2021-02-23 · proof | |
| Free cash flow | -$113.6 million | -$96.8 million | 10-K 2021-02-23 · proof | |
| Total assets | $167.9 million | $188.8 million | -11.1% | 10-K 2021-02-23 · proof |
| Total liabilities | $31.7 million | $26.5 million | +19.7% | 10-K 2021-02-23 · proof |
| Cash and cash equivalents | $158 million | $181.2 million | -12.8% | 10-K 2021-02-23 · proof |
- What was Odonate Therapeutics, Inc.'s operating income in fiscal 2020?
- Odonate Therapeutics, Inc. reported operating income of -$127.4 million for fiscal 2020 (the year ended Dec 31, 2020), against -$114.9 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
- What was Odonate Therapeutics, Inc.'s net income in fiscal 2020?
- Odonate Therapeutics, Inc. reported net income of -$126.4 million for fiscal 2020 (the year ended Dec 31, 2020), against -$111.8 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
- What was Odonate Therapeutics, Inc.'s cash from operating activities in fiscal 2020?
- Odonate Therapeutics, Inc. reported cash from operating activities of -$113.1 million for fiscal 2020 (the year ended Dec 31, 2020), against -$96.6 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
- What was Odonate Therapeutics, Inc.'s free cash flow in fiscal 2020?
- Odonate Therapeutics, Inc. reported free cash flow of -$113.6 million for fiscal 2020 (the year ended Dec 31, 2020), against -$96.8 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
- What are Odonate Therapeutics, Inc.'s total assets?
- As of Dec 31, 2020, Odonate Therapeutics, Inc. reported total assets of $167.9 million, against $188.8 million a year earlier (-11.1%). Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
- What are Odonate Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2020, Odonate Therapeutics, Inc. reported total liabilities of $31.7 million, against $26.5 million a year earlier (+19.7%). Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
- What are Odonate Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2020, Odonate Therapeutics, Inc. reported cash and cash equivalents of $158 million, against $181.2 million a year earlier (-12.8%). Source: the 10-K filed with the SEC on Feb 23, 2021. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1717452&period_type=annual&limit=5"Information only, not investment advice.